Bicara Therapeutics (NASDAQ:BCAX) Raised to "Strong-Buy" at BMO Capital Markets
BMO Capital Markets upgraded Bicara Therapeutics (NASDAQ:BCAX) to a "strong-buy" rating, with other analysts maintaining a "Moderate Buy" consensus and an average target price of $32.64. The company's shares rose by 3.8% to $25.86, following a quarterly EPS report of negative $0.82, which met consensus estimates. Insider selling occurred last quarter, but major institutional investors like BlackRock and Janus Henderson increased their holdings.
Bicara Therapeutics Initiated at Outperform by BMO Capital
BMO Capital has initiated coverage on Bicara Therapeutics with an Outperform rating. This indicates a positive outlook from the firm regarding the company's future performance. The specific reasons for this rating are not detailed in this short blurb.
BMO Capital Initiates Bicara Therapeutics at Outperform
BMO Capital has initiated coverage on Bicara Therapeutics with an Outperform rating. This rating suggests that BMO Capital expects Bicara Therapeutics' stock to perform better than the broader market or its sector peers. The initiation of coverage by a major financial institution like BMO Capital often brings increased attention and potential investor interest to the company.
BICARA THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $35
BMO has initiated coverage on Bicara Therapeutics Inc. (BCAX.O) with an Outperform rating. The financial institution has set a price target of $35 for the company's stock. This news indicates a positive outlook from BMO regarding Bicara Therapeutics' future performance.
BMO starts Bicara Therapeutics stock at Outperform on cancer drug potential
BMO Capital initiated coverage on Bicara Therapeutics (NASDAQ:BCAX) with an Outperform rating and a $35 price target, citing the potential of its bispecific drug candidate, ficerafusp alfa, for head and neck squamous cell carcinoma. The firm anticipates a key value inflection point in mid-2027 and potential accelerated approval by 2028, projecting peak sales of $2 billion. Other analysts also maintain positive outlooks, with price targets ranging up to $39, despite the stock's significant surge over the past year.
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of "Moderate Buy" by Brokerages
Bicara Therapeutics Inc. (NASDAQ:BCAX) has received an average "Moderate Buy" rating from fourteen analysts, with an average 12-month price target of $32.40. Despite insider share sales by the CEO and CFO totaling approximately $3.27 million over the past quarter, the company reported a quarterly loss of $0.82 per share, matching analyst expectations. Bicara Therapeutics is a clinical-stage biopharmaceutical company focusing on neurohormone-based therapies for psychiatric and neurological disorders.
Bicara Therapeutics (BCAX) Is Down 13.5% After Leadership Overhaul And ESOP Shelf Filing - Has The Bull Case Changed?
Bicara Therapeutics (BCAX) has seen a 13.5% drop following a significant leadership reshuffle, including new executives for CEO, CFO, COO, Chief Business Officer, and Chief Legal Officer roles. This overhaul, coupled with a wider net loss of US$55.44 million and an ESOP shelf filing for up to 700,000 shares, signals a shift towards commercialization, particularly for ficerafusp alfa. Investors are now evaluating whether these changes and the associated dilution risk will impact the company's investment narrative ahead of the mid-2027 interim trial readout.
SCS Capital Management LLC Purchases New Shares in Bicara Therapeutics Inc. $BCAX
SCS Capital Management LLC has acquired 53,430 shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) worth approximately $1.586 million, establishing a new position in the company. Despite insider selling activity totaling $3.27 million, other institutional investors have also adjusted their holdings. Analysts maintain a "Moderate Buy" rating for Bicara Therapeutics with an average price target of $32.73, while the company reported a quarterly loss in line with expectations.
Walleye Capital LLC Makes New $10.49 Million Investment in Bicara Therapeutics Inc. $BCAX
Walleye Capital LLC has made a new $10.49 million investment in Bicara Therapeutics Inc. (NASDAQ:BCAX), acquiring 353,226 shares, representing approximately 0.54% of the company. Other institutional investors also increased their stakes, while company insiders sold shares worth $3.27 million over the past three months. Analysts maintain a "Moderate Buy" consensus rating with an average target price of $32.73 for BCAX.
Bicara Therapeutics (BCAX) awards 285,000 stock options to CFO Jennifer Larson
Bicara Therapeutics Inc. has granted 285,000 stock options to its CFO, Jennifer Larson, on August 12, 2026, with an exercise price of $24.63 per share. These options will vest over time, with 25% vesting on August 12, 2027, and the remainder in equal quarterly installments, contingent on her continued service. Following this grant, Ms. Larson directly holds 285,000 derivative securities of this type, which expire on August 12, 2036.
Bicara Therapeutics (BCAX) CFO Jennifer Larson submits initial Form 3
Bicara Therapeutics Inc.'s Chief Financial Officer, Jennifer Larson, has submitted an initial Form 3, indicating her status as an officer but showing no reportable equity holdings or transactions at this time. The filing includes a reference to an attached Exhibit 24, which grants a Power of Attorney. This Form 3 serves as the initial statement of beneficial ownership for the CFO of BCAX.
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics Inc. announced an inducement grant to Jennifer Larson, its new Chief Financial Officer, effective August 12, 2026. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of common stock at an exercise price of $24.63 per share, vesting over approximately four years. This grant was made under Bicara's 2026 Inducement Plan and was approved by independent directors as a material inducement for her employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced an inducement grant to Jennifer Larson, the new Chief Financial Officer, under Nasdaq Listing Rule 5635(c)(4). Ms. Larson received a non-qualified stock option to purchase 285,000 shares of Bicara's common stock at an exercise price of $24.63 per share. This grant vests over time, with a quarter vesting on her first anniversary and the remainder in quarterly installments, contingent on her continued employment.
Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX
Dimensional Fund Advisors LP significantly increased its stake in Bicara Therapeutics Inc. by 166.9% in the first quarter, now holding 109,261 shares valued at $2.17 million. Several other institutional investors also raised their positions, while insider sales have occurred. Bicara Therapeutics maintains a "Moderate Buy" consensus rating with an average price target of $32.73, and investors are looking forward to clinical progress, particularly the planned 2026 enrollment for the ficerafusp alfa study.
Bicara Therapeutics (NASDAQ:BCAX) COO Sells $524,625.00 in Stock
Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp sold 18,750 shares of the company's stock for $524,625 under a pre-arranged Rule 10b5-1 plan, reducing his position by 9.36%. The company's stock rose 3.7% to $24.63, and it reported a quarterly loss of $0.82 per share, matching analyst expectations. Analyst sentiment for BCAX is mixed but generally positive, with a consensus "Moderate Buy" rating and an average price target of $32.73.
Bicara Therapeutics (BCAX) CFO exercises options, sells 12,500 shares under 10b5-1 plan
Bicara Therapeutics Inc.'s Chief Financial Officer, Hyep Ivan, exercised stock options for 12,500 shares at $3.7898 per share and simultaneously sold these shares at a weighted average price of $27.9673 per share. These transactions, executed on August 10, 2026, were conducted under a Rule 10b5-1 trading plan adopted on March 31, 2026. Following these trades, Ivan's reported option position decreased to 26,336 stock options, which vest in quarterly installments and expire in 2033.
Bicara Therapeutics (BCAX) President & COO exercises 18,750 options and sells 18,750 shares
Bicara Therapeutics Inc. President and COO Ryan Cohlhepp exercised 18,750 stock options at $3.7898 per share and simultaneously sold 18,750 common shares at a weighted average price of $27.9751. This transaction was conducted under a Rule 10b5-1 trading plan adopted on March 31, 2026. Following these transactions, Cohlhepp retains 51,752 stock options expiring in 2033 and 181,641 common shares.
Bicara Therapeutics Insider Sold Shares Worth $524,533, According to a Recent SEC Filing
An insider at Bicara Therapeutics sold shares valued at $524,533, as per a recent SEC filing. This transaction is one of several insider sales reported for the company around the same date, alongside other corporate news including earnings reports and analyst rating adjustments.
Mizuho raises Bicara Therapeutics stock price target on HNSCC positioning
Mizuho has increased its price target for Bicara Therapeutics (NASDAQ: BCAX) to $20 from $18, citing improved positioning for its ficera drug in head and neck squamous cell carcinoma. The company recently reported Q2 2026 earnings, provided pipeline updates, and announced executive leadership changes. Despite competitive risks, Bicara expects substantial enrollment in its FORTIFI-HN01 trial by end-2026 and interim data by mid-2027.
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
Bicara Therapeutics Inc. reported better-than-expected Q2 losses of 82 cents per share, surpassing analyst estimates. Following the earnings, BTIG and Wells Fargo analysts adjusted their price targets for BCAX, with BTIG maintaining a "Buy" rating and raising its price target from $28 to $39, and Wells Fargo maintaining an "Equal-Weight" rating and raising its target from $16 to $23. Despite beating estimates, the company's shares dipped 14.3% to $23.76.
Bicara Therapeutics Inc. 2026: Revenue ($55.76M), Net income ($55.44M), EPS ($0.82) — 10-Q Summary
Bicara Therapeutics Inc. reported a wider loss in 2026 compared to the previous year, with a total comprehensive loss of ($55.76M) and a net loss of ($55.44M). This was attributed to increased clinical and development activity as the company prepares for a planned Phase 3 program for its FORTIFI-HN01 program. The company also highlighted positive trial signals from Phase 1b, dose flexibility initiatives, and operational scale-up, including increased staffing and spending.
Mizuho raises Bicara Therapeutics stock price target on HNSCC positioning
Mizuho increased its price target for Bicara Therapeutics (NASDAQ:BCAX) to $20 from $18, citing improved positioning of its ficera drug candidate for head and neck squamous cell carcinoma. The company reported Q2 2026 earnings, updated its pipeline, and announced executive leadership changes. Bicara anticipates completing enrollment for the FORTIFI-HN01 trial by year-end 2026 and releasing interim topline data in mid-2027, with initial data for ficera in colorectal cancer expected by the end of 2026.
Bicara Therapeutics Reports Second Quarter 2026 Progress
Bicara Therapeutics announced its second-quarter 2026 financial results and significant leadership transitions, including Ryan Cohlhepp becoming President & CEO in January 2027. The company is on track for substantial enrollment in its pivotal FORTIFI-HN01 study by year-end, with topline results expected mid-2027, and reported $497.3 million in cash, cash equivalents, and marketable securities, projected to fund operations into the first half of 2029. They also initiated the FORTIFI-FLEX alternate dosing study and presented positive extended follow-up data for ficerafusp alfa in HPV-negative HNSCC.
Bicara Therapeutics (BCAX) deepens R&D investment while holding $497M in cash
Bicara Therapeutics (BCAX) reported a net loss of $55.4 million for Q2 2026 and $111.6 million for the first half of 2026, primarily due to increased R&D and administrative expenses. Despite the larger loss, the clinical-stage oncology company holds a strong cash position of $497.3 million, expected to fund operations into the first half of 2029. The company is advancing its lead asset, ficerafusp alfa, through a pivotal Phase 2/3 trial and other studies for solid tumors.
Morgan Stanley raises Bicara Therapeutics stock price target on cash runway
Morgan Stanley has increased its price target for Bicara Therapeutics (NASDAQ:BCAX) from $37 to $39, maintaining an Overweight rating due to the company's strong cash position. Bicara reported $497.3 million in cash and equivalents, projected to fund operations into the first half of 2029, a factor influencing the updated discounted cash flow analysis. Despite a significant 177% return over the past year, the stock is currently considered overvalued relative to its fair value.
Bicara Therapeutics Releases Q2 2026 Financial Results
Bicara Therapeutics Inc. (BCAX) reported a narrower-than-expected loss of $0.82 per share for Q2 2026, surpassing Wall Street's estimate of a $0.85 loss. Despite this, the company's net loss widened to $55.4M as it continues significant investments in its clinical development programs for bifunctional therapies targeting solid tumors. Analyst sentiment remains positive with 10 buy ratings and 4 hold ratings, reflecting confidence in its therapeutic approach despite ongoing operating losses.
Bicara Therapeutics Inc. (BCAX) Investor Outlook: Tapping into a 14% Upside with Innovative Biotech Solutions
Bicara Therapeutics Inc. (BCAX) is a clinical-stage biopharmaceutical company focused on innovative cancer treatments, particularly bifunctional therapies for solid tumors. Despite operating at a loss, which is common for early-stage biotech firms, analysts project a 14.36% upside for the stock, driven by its promising pipeline and investor confidence. The company's lead program, ficerafusp alfa, is a cutting-edge bifunctional antibody that highlights its commitment to redefining cancer treatment.
Bicara Therapeutics (BCAX.US) will release its earnings report before market open on August 11.
Bicara Therapeutics (BCAX.US) is scheduled to release its earnings report on August 11, before the market opens. This announcement informs investors and the public about the upcoming financial disclosure.
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company, announced it will report its second-quarter 2026 financial results and provide business updates on Tuesday, August 11, 2026, before market open. The company will host a conference call at 8:30 a.m. ET on the same day to discuss these results. Bicara focuses on developing transformative bifunctional therapies for solid tumors, with its lead program ficerafusp alfa currently in development.
Bicara Therapeutics Q2 Results: Financial update scheduled for August 11, 2026
Bicara Therapeutics Inc. will release its Q2 2026 financial results on August 11, 2026, before market open, followed by a conference call at 8:30 a.m. ET. The company, a clinical-stage biopharmaceutical firm, is focused on developing bifunctional therapies for solid tumors, with its lead program ficerafusp alfa targeting head and neck squamous cell carcinoma and other solid tumor types. A webcast of the call will be available on the company's investor relations page, with a replay accessible for 30 days.
Bicara Therapeutics will detail second-quarter results Aug. 11
Bicara Therapeutics (NASDAQ: BCAX) announced it will report its second quarter 2026 financial results and provide business updates before the market opens on Tuesday, August 11, 2026. The company will host a conference call at 8:30 a.m. ET the same day to discuss these updates. Investors can register online to receive dial-in details and a unique PIN for the call, and a live webcast will be available via the company's website.
Bicara Therapeutics to Report Second Quarter 2026 Financial
Bicara Therapeutics Inc. announced it will report its second quarter 2026 financial results and business updates on Tuesday, August 11, 2026, before the market opens. The company will host a conference call at 8:30 a.m. ET on the same day to discuss these updates. Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, with its lead program ficerafusp alfa targeting EGFR and TGF-β.
Rock Springs Capital Management LP Raises Stock Holdings in Bicara Therapeutics Inc. $BCAX
Rock Springs Capital Management LP increased its stake in Bicara Therapeutics Inc. by 14% in the first quarter, now holding 489,095 shares valued at $9.7 million. Despite the company missing its Q1 earnings estimates with a loss of $0.93 per share, Bicara's stock opened 2.9% higher at $27.81. Analysts maintain a "Moderate Buy" rating for BCAX with an average price target of $30.27, although insiders have recently sold shares worth approximately $2.37 million.
Will New Oncology Veterans on Bicara Therapeutics' (BCAX) Board Reshape Its Late-Stage Strategy?
Bicara Therapeutics (BCAX) has appointed Jeremy Bender and Christy Oliger to its Board of Directors, bringing extensive oncology drug development and commercialization experience. These appointments could significantly influence the company's late-stage strategy for its lead asset, FICERA, particularly concerning its FORTIFI HN01 trial and future commercialization. The article discusses how these new board members might reshape the company's investment narrative and risk profile, especially as Bicara aims for substantial revenue growth by 2029.
Bicara Therapeutics (BCAX) director reports initial Form 3 filing
Bicara Therapeutics Inc. director Christy J. Oliger has filed an initial Form 3, an Initial Statement of Beneficial Ownership. The filing indicates no current equity or derivative security holdings and no reported transactions, with a reference to a Power of Attorney document. This report signifies the initial disclosure of ownership for a newly appointed director.
Will New Oncology Veterans on Bicara Therapeutics' (BCAX) Board Reshape Its Late-Stage Strategy?
Bicara Therapeutics recently appointed Jeremy Bender and Christy Oliger, experienced oncology executives, to its Board of Directors, while Kiran Mazumdar-Shaw retired. These appointments are expected to influence Bicara's late-stage development and commercialization decisions, particularly regarding its FICERA program for head and neck cancer. Investors will be watching how this expertise shapes trial execution and launch planning, though the core risk/reward of the single-asset focus remains.
Bicara Therapeutics (BCAX) awards 38,950 stock options to board director
Bicara Therapeutics (BCAX) director Christy J. Oliger was granted 38,950 stock options with an exercise price of $26.88 per share, expiring on July 28, 2036. The options will vest one-third on July 28, 2027, with the remainder vesting in 24 equal monthly installments, contingent on her continued service. This transaction is an equity-based compensation and not an open-market purchase or sale.
Bicara Therapeutics grants options to director | BCAX Insider Trading
Bicara Therapeutics (BCAX) has granted its director, Jeremy Bender, 38,950 stock options. These options have an exercise price of $26.88 per share and expire on July 28, 2036. The shares will vest in stages, with one-third vesting on July 28, 2027, and the remainder vesting in 24 equal monthly installments, contingent on Bender's continued service.
Bicara Therapeutics Inc. (BCAX) director Jeremy Bender files ownership report
Bicara Therapeutics Inc. director Jeremy Bender has filed an initial statement of beneficial ownership (Form 3), indicating his role as a director. The filing reports no transactions or specific equity holdings for Bender and refers to an accompanying Exhibit 24 - Power of Attorney. This filing clarifies that Bender does not currently hold any direct equity or derivative securities in BCAX, as of the reporting date.
Press Release: Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
Bicara Therapeutics has announced the appointments of Jeremy Bender, Ph.D., and Christy Oliger to its Board of Directors. Bender brings
Bicara Therapeutics Oliger Recently Served as Senior Vice Pres of the Oncology Business Unit at Genentech >BCAX
Bicara Therapeutics has appointed Natalie R. Oliger, an executive with significant oncology experience from Genentech, to its Board of Directors. Her appointment is expected to provide valuable strategic insights as Bicara advances its pipeline.
Bicara Therapeutics Announces Appointments Of Jeremy Bender And Christy Oliger To Board Of Directors
Bicara Therapeutics has announced the appointments of Jeremy Bender and Christy Oliger to its Board of Directors. This news was reported by Refinitiv and is available on TradingView. The article indicates that full access to the content is available on TradingView, along with other news from Reuters.
Bicara Therapeutics adds two directors to board
Bicara Therapeutics Inc. (NASDAQ:BCAX) has announced the appointment of Jeremy Bender and Christy Oliger to its board of directors, expanding its leadership team. Jeremy Bender brings over 20 years of experience in biotechnology, including leading Day One Biopharmaceuticals through its acquisition. Christy Oliger adds more than 30 years of commercial and operating experience from biopharmaceutical organizations like Genentech, where she managed a portfolio with over $13 billion in US revenue.
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
Bicara Therapeutics has appointed Jeremy Bender, Ph.D., MBA, and Christy Oliger to its Board of Directors, bringing extensive experience in biotechnology corporate strategy and biopharmaceutical commercialization. These appointments are intended to strengthen Bicara's leadership as it transitions from a clinical-stage company to one focused on commercializing its lead therapy, ficerafusp alfa. Concurrently, Kiran Mazumdar-Shaw retired from the Board, with Bicara acknowledging her foundational contributions.
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
Bicara Therapeutics Inc. (Nasdaq: BCAX) has announced the appointments of Jeremy Bender, Ph.D., MBA, and Christy Oliger to its Board of Directors. These strategic additions bring extensive corporate strategy, commercial, and operational experience to Bicara during a pivotal time as the company advances its lead program, ficerafusp alfa. Concurrently, Kiran Mazumdar-Shaw has retired from the Board, with the company acknowledging her foundational contributions.
BlackRock (BCAX holder) discloses 5.4% Bicara Therapeutics stake on Schedule 13G
BlackRock, Inc. has filed a Schedule 13G, disclosing a passive ownership stake of 5.4% in Bicara Therapeutics Inc. (BCAX). As of June 30, 2026, BlackRock beneficially owned 3,536,271 shares of Bicara's common stock, holding sole voting power over 3,464,981 shares and sole dispositive power over all 3,536,271 shares. The filing indicates that no single client of BlackRock holds more than five percent of Bicara's outstanding common shares.
Bicara Therapeutics Inc (BCAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Bicara Therapeutics Inc (BCAX), detailing its performance based on various indicators and moving averages. It offers insights into the stock's current technical status, including buy/sell signals from MACD, RSI, and different moving averages. The analysis concludes with a neutral signal for the stock based on these technical factors.
Bicara Therapeutics Inc (BCAX) Cash Flow
This article provides a detailed cash flow statement for Bicara Therapeutics Inc (BCAX), including operating, investing, and financing cash flows presented quarterly and annually. It also includes an FAQ section explaining key cash flow concepts and specific figures for BCAX, such as operating cash flow, capital expenditures, and free cash flow. The data covers several fiscal quarters from FY2023Q3 to FY2026Q1, highlighting changes year-over-year.
BCAX|Bicara Therapeutics Inc|Price:27.020|Chg%:-0.710
This article provides a detailed financial overview of Bicara Therapeutics Inc (BCAX), including its current stock price, market capitalization, key financial figures, and recent performance. It also includes analyst ratings, indicators, and company information, emphasizing its focus on developing bifunctional therapies for solid tumors. The company's lead program, ficerafusp alfa, aims to target both EGFR and TGF-b for potent anti-tumor activity.
BCAX|Bicara Therapeutics Inc|Price:27.020|Chg%:-0.710
Bicara Therapeutics Inc. (BCAX) is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Their lead program, ficerafusp alfa, targets EGFR and TGF-b to block cancer cell survival and immunosuppression. The company, which IPO'd on September 13, 2024, is led by CEO Dr. Claire Mazumdar and has 55 employees.
